

Joint Biological Agent Identification Diagnostic System (JBAIDS)

Protects personnel by rapidly identifying low-levels of biological warfare agents and other pathogens encountered in field or hospital clinical laboratories.



DESCRIPTION AND SPECIFICATIONS

The Joint Biological Agent Identification Diagnostic System (JBAIDS) can identify biological agents in a variety of environmental and clinical samples at or below 1,000 colony-forming units or 10,000 plaque-forming units per milliliter.

JBAIDS includes a clinical instrument based on commercial, off-the-shelf, non-developmental item technology requiring limited modification to meet operational requirements. Integrated with this instrument are reagent test kits for pathogen identification and protocols for sample preparation that, when used together, can be cleared by the Food and Drug Administration as a diagnostic test.

Detection Sensitivity: Equal to or better than 85 percent for identification of target agents at specified limit of detection concentrations.


Detection Specificity: Equal to or better than 90 percent for identification of target agents at specified limit of detection concentrations.

PROGRAM STATUS

- 4QFY03 Contract award
- 2QFY04 Critical design review
- 2QFY04 Developmental testing
- 4QFY04 Operational assessment; Milestone C

PROJECTED ACTIVITIES

- 3QFY05 Initial operational test and evaluation
- 4QFY05 JBAIDS Block II Competitive fly-off
- FQFY05 Milestone C (full rate decision)



CONTRACTORS

Idaho Technologies (Salt Lake City, UT)

INVESTMENT COMPONENT

Modernization

ACQUISITION PHASE

- System Development and Demonstration